Billing, Coding, and Payment for IPP LARC Services

Receiving Payment for Optimized Care





ACOG disclaimer

This information is designed as an educational resource to aid clinicians in providing obstetric and gynecologic care, and use of this information is voluntary. This information should not be considered as inclusive of all proper treatments or methods of care or as a statement of the standard of care. It is not intended to substitute for the independent professional judgment of the treating clinician. Variations in practice may be warranted when, in the reasonable judgment of the treating clinician, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology. The American College of Obstetricians and Gynecologists reviews its publications regularly; however, its publications may not reflect the most recent evidence.

Any updates to this document can be found on www.acog.org or by calling the ACOG Resource Center.

While ACOG makes every effort to present accurate and reliable information, this publication is provided "as is" without any warranty of accuracy, reliability, or otherwise, either express or implied. ACOG does not guarantee, warrant, or endorse the products or services of any firm, organization, or person. Neither ACOG nor its officers, directors, members, employees, or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented.

© 2019 by the American College of Obstetricians and Gynecologists, 409 12th Street SW, PO Box 96920, Washington, DC 20090-6920. Individuals and groups providing patient care or clinical education in family planning have permission to copy all or any portion of this slide set for noncommercial, educational purposes, provided that no modifications are made and proper attribution is given.

Speaker disclosures

Brad Hart – No disclosures to report



Topics covered in presentation

- **Section 1: The unmet patient need for postpartum contraception**
- **Section 2: The codes used to report contraceptive services**
 - a. Procedures
 - **b.** Supplies
 - c. Diagnoses
- Section 3: Reporting long-acting reversible contraception (LARC) services in the context of immediate postpartum (IPP) services
- Section 4: Accessing information concerning Medicaid IPP LARC reimbursement policies and identifying the most common reporting methodologies



Learning Objectives

- Understand the benefits of offering immediate postpartum contraceptive services
- 2. Explain the appropriate use of the Current Procedural Terminology (CPT) code and the International Classification of Disease, Tenth Edition (ICD-10) for LARC-related services
- 3. Identify resources from the American College of Obstetricians and Gynecologists (ACOG) available to address common LARC-related coding questions



UNMET PATIENT NEED

for Postpartum Contraception



Challenges with initiating postpartum contraception

- As many as 40% of women do not return for the 6 week postpartum visit
 - Even lower in under-resourced areas, further contributing to health disparities
- Non-breastfeeding women can ovulate as early as 25 days postpartum
 40% of women will ovulate by 6 weeks postpartum
- 57% of women are sexually active by 6 weeks postpartum



Challenges with initiating postpartum contraception

Patients may have difficulty returning for a postpartum visit because of:

- Childcare obligations
- Unable to get off work
- Unstable housing
- No transportation
- Communication or language barrier
- Lack of insurance coverage or potential expiration of Medicaid eligibility



What is LARC?

• LARC stands for long-acting reversible contraception

• 2 types of LARC: the <u>intrauterine device</u> and the <u>contraceptive implant</u>, which are the most effective reversible forms of contraception



Comparing LARC Methods

	ParaGard [®] CopperT 380A	Liletta®	Mirena®	Kyleena®	Skyla®	Nexplanon [®]		
Hormone and Dose	Non-hormonal	(18.6 mcg/day) (20 mcg/day)		19.5mg LNG (17.5 mcg/day)	13.5mg LNG (14 mcg/day)	68mg ENG (35-45 mcg/day)		
Efficacy		> 99%						
FDA- Approved Duration of Use*	10 years	6 years	5 ye	ars	3 years			
Expected Bleeding Patterns	Typically heavier	associated with hormone dose		Typically lighter, often unpredictable				

^{*} Ongoing studies suggest high efficacy with extended use beyond FDA-approved durations

What is immediate postpartum LARC?

LARC methods are available to women in the hospital after a delivery before discharge

- ACOG, CDC, WHO, and Cochrane Reviews all support immediate postpartum LARC as a safe and effective option
- Can be an ideal time to provide LARC methods for many women who want them



IPP LARC can help meet patients' needs

- Safe
- Convenient
- Highly effective
- Reversible
- Forgettable
- High continuation rates



THE CODES USED

To Report Contraceptive Services



The Code Sets

- Procedure/Supply Codes:
 - 1. Current Procedural Terminology (CPT®)
 - Used by physicians/providers to report procedural and cognitive services
 - Known as Level I codes
 - 2. International Classification of Disease, 10th edition, Procedural Coding System (ICD-PCS)
 - Used by hospitals/facilities to report procedures
 - 3. Healthcare Common Procedure Coding System (HCPCS)
 - Known as Level II codes
 - Describes certain procedures, but most commonly used to report supplies, materials, etc.



The Code Sets

- Diagnostic Codes
 - 1. International Classification of Disease, 10th edition, Clinical Modification (ICD-10-CM)
 - Used by hospitals/inpatient facilities to report diagnoses

Procedure Codes (CPT®)

Intrauterine Contraception

Insertion of intrauterine device (IUD)

Subdermal Implantable Contraception

11981 Insertion, non-biodegradable drug delivery implant



Devices (HCPCS Codes)

HCPCS Code	Brand Name	Description
J7296	Kyleena™	Levonorgestrel releasing intrauterine (LNG) system, 19.5 mg
J7297	Liletta®	Levonorgestrel-releasing intrauterine (LNG) system, 52mg
J7298	Mirena®	LNG-releasing intrauterine system, 52mg
J7300	ParaGard®	Intrauterine copper contraceptive (no hormones)
J7301	Skyla®	LNG-releasing intrauterine system, 13.5 mg
J7307	Nexplanon®	Etonogestrel implant 68mg

Diagnoses (ICD-10-CM)

Initial	Description	Surveillance/Other
Z30.014	IUD Insertion	Z30.430
	IUD Checking	Z30.431
	IUD Removal	Z30.432
	IUD Removal/Reinsertion	Z30.433
Z30.017	Implantable subdermal	Z30.46

BILLING FOR IPP LARC SERVICES




The necessity of this discussion


- Physicians are paid separately for LARC devices they provide in the office
- Hospitals are paid a flat rate for delivery services, which typically includes the LARC device
 - There's a decided lack of motivation to provide these services
 - The solution—<u>compensate</u> <u>separately</u> for the devices



44 states currently reimburse for IPP LARC







Medicaid policies









Billing and Reimbursement



8 | Page



BULLE Administration S

Bulletin Number: MSA 18-22

Distribution: Family Planning Clinics, Hospital, Maternal & Infant Support, and

Medicaid Health Plans

Issued: August 31, 2018

Subject: Inpatient Long-Acting Reversible Contraception (LARC)

Reimbursement

Effective: October 1, 2018

Programs Affected: Medicaid, Healthy Michigan, Maternity Outpatient Medical Services

NOTE: Implementation of this policy is contingent upon State Plan Amendment approval from the Centers for Medicare & Medicaid Services (CMS).

The purpose of this policy bulletin is to establish hospital reimbursement for immediate postpartum Long-Acting Reversible Contraception (LARC) implants and intrauterine devices (IUDs) separate from the maternity Diagnosis Related Group (DRG) payment. Effective for dates-of-service on or after October 1, 2018, separate reimbursement will be available for LARC devices when the device is provided immediately postpartum in an inpatient hospital setting prior to discharge.

For reimbursement of the LARC device, the facility must submit a separate professional claim with place of service 21 – Inpatient Hospital. The professional claim would include the hospital as the billing provider and the practitioner performing the related procedure as the rendering provider. When billing for an IUD or contraceptive implant device, the provider must use the appropriate Healthcare Common Procedure Coding System (HCPCS) Level II procedure code and National Drug Code (NDC).

Facilities participating in the federal 340B Drug Pricing Program are required to continue to bill 340B actual acquisition cost for the LARCs. Drugs and devices obtained through the 340B program must be indicated on the claim using the U6 modifier. Payment for the LARC will be made in accordance with the Practitioner Medicaid fee schedule in effect on the date-of-service for the procedure code billed.

Michigan Medicaid will continue to reimburse hospitals for related obstetrical services in



MEDICAL ASSISTANCE BULLETIN

ISSUE DATE

November 26, 2016

December 1, 2016

01-16-33, 08-16-31, 09-16-30, 28-16-02, 31-16-35, 33-16-29

SUBJECT

MA Program Fee Schedule Updates for Certain Family Planning Services GeesaM. allen

Leesa M. Allen, Deputy Secretary
Office of Medical Assistance Programs

IMPORTANT REMINDER: All providers must revalidate their MA enrollment every 5 years. Providers should log into PROMISe to check their revalidation date and submit a revalidation application at least 60 days prior. Enrollment (revalidation) applications may be found at

http://www.dhs.pa.gov/provider/promise/enrollmentinformation/S 001994

PURPOSE:

The purpose of this bulletin is to notify providers of updates to the Medical Assistance (MA) Program Fee Schedule for certain family planning and family planning-related services, effective with dates of service on and after December 1, 2016.

SCOPE:

This bulletin applies to MA enrolled acute care general hospitals and providers who render family planning services to MA beneficiaries in the MA Fee-for-Service (FFS) delivery system.

Providers who render family planning services to MA beneficiaries in the managed care delivery system should direct any fee-related questions to the appropriate managed care organization.

BACKGROUND/DISCUSSION:

As one method to prevent unplanned pregnancies, long-acting reversible contraception LARC) can be used immediately postpartum to facilitate adequate spacing between pregnancies. Research demonstrates that inadequate birth spacing can heighten the risk of

COMMENTS AND QUESTIONS REGARDING THIS BULLETIN SHOULD BE DIRECTED TO:

The appropriate toll free number for your provider type

Visit the Office of Medical Assistance Programs Web site at http://www.dhs.pa.gov/provider/healthcaremedicalassistance/index.htm



TOOLS FOR REPORTING IPP LARC SERVICES

Professional/Physician & Facility-Based Charges



CMS* - 1500 Claim Form


- Form used nation-wide for IPP LARC professional charge
 - Possibly required by some commercial payers for inpatient services
- Outpatient/Physician Service
- Physicians use this claim form to report services

*Center for Medicare & Medicaid Services

1500			
HEALTH INSURANCE CLAIM FORM APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE 08/05			
APPROVED BY NATIONAL UNIFORM CLAIM COMMITTEE 08/05			PICA T
1. MEDICARE MEDICAID TRICARE CHAMPUS CHAMP	VA GROUP FECA OTHE	R 1a. INSURED'S I.D. NUMBER	(For Program in Item 1)
(Medicare #) (Medicaid #) (Sponsor's SSN) (Member			
PATIENT'S NAME (Last Name, First Name, Middle Initial)	3. PATIENT'S BIRTH DATE SEX	 INSURED'S NAME (Last Name, First Name, I 	Middle Initial)
5. PATIENT'S ADDRESS (No., Street)	6. PATIENT RELATIONSHIP TO INSURED	7. INSURED'S ADDRESS (No., Street)	
	Self Spouse Child Other		
CITY STATE		CITY	STATE
ZIP CODE TELEPHONE (Include Area Code)	Single Married Other	ZIP CODE TELEPHONE	(Include Area Code)
()	Employed Full-Time Part-Time Student	()
OTHER INSURED'S NAME (Last Name, First Name, Middle Initial)	10. IS PATIENT'S CONDITION RELATED TO:	11. INSURED'S POLICY GROUP OR FECA NU	MBER
a. OTHER INSURED'S POLICY OR GROUP NUMBER	a, EMPLOYMENT? (Current or Previous)	a INSURED'S DATE OF BIDTU	SEX
	YES NO	a. INSURED'S DATE OF BIRTH MM DD YY	F F
b. OTHER INSURED'S DATE OF BIRTH SEX	b. AUTO ACCIDENT? PLACE (State	b. EMPLOYER'S NAME OR SCHOOL NAME	
M F	YES NO	- INDIDANCE DI ANTINE CO COCC	STATE STATE [(Include Area Code)) MBER SEX F AME
c. EMPLOYER'S NAME OR SCHOOL NAME	c. OTHER ACCIDENT?	c. INSURANCE PLAN NAME OR PROGRAM N	AME
d. INSURANCE PLAN NAME OR PROGRAM NAME	10d. RESERVED FOR LOCAL USE	d. IS THERE ANOTHER HEALTH BENEFIT PL	AN?
			and complete item 9 a-d.
READ BACK OF FORM BEFORE COMPLETIN 12. PATIENT'S OR AUTHORIZED PERSON'S SIGNATURE I authorize the	e release of any medical or other information necessary	 INSURED'S OR AUTHORIZED PERSON'S payment of medical benefits to the undersign 	
to process this claim. I also request payment of government benefits either below.	r to myself or to the party who accepts assignment	services described below.	
SIGNED	DATE	SIGNED	
14. DATE OF CURRENT: ILLNESS (First symptom) OR INJURY (Accident) OR	. IF PATIENT HAS HAD SAME OR SIMILAR ILLNESS GIVE FIRST DATE MM DD YY	B. 16. DATES PATIENT UNABLE TO WORK IN CO	URRENT OCCUPATION MM DD YY
17. NAME OF REFERRING PROVIDER OR OTHER SOURCE		18. HOSPITALIZATION DATES RELATED TO C	CURRENT SERVICES
	b. NPI	FROM TO	
19. RESERVED FOR LOCAL USE			HARGES
21. DIAGNOSIS OR NATURE OF ILLNESS OR INJURY (Relate Items 1, 2	2, 3 or 4 to Item 24E by Line)	22 MEDICAID RESURMISSION	
1	·		EF. NO.
		23. PRIOR AUTHORIZATION NUMBER	
24. A. DATE(S) OF SERVICE B. C. D. PROC	EDURES, SERVICES, OR SUPPLIES E.	F. G. H. I.	J.
From To PLACE OF (Exp MM DD YY MM DD YY SERVICE EMG CPT/HC	(ain Unusual Circumstances) DIAGNOSI		J. RENDERING PROVIDER ID. #
		NPI	
		NPI	
		NPI	
		NPI	
		NPI	
25. FEDERAL TAX I.D. NUMBER SSN EIN 26. PATIENT'S	ACCOUNT NO. 27. ACCEPT ASSIGNMENT?	28. TOTAL CHARGE 29. AMOUNT PAI	
		\$ \$	s
	ACILITY LOCATION INFORMATION	33. BILLING PROVIDER INFO & PH # ()
31. SIGNATURE OF PHYSICIAN OR SUPPLIER INCLUDING DEGREES OR CREDENTIALS (I certify that the statements on the reverse apply to this bill and are made a part thereof.)			
INCLUDING DEGREES OR CREDENTIALS (I certify that the statements on the reverse	D b.	a. b.	

UB-04 Claim Form

- Form used nation-wide for IPP LARC facilitybased service charge
- Hospitals use this claim form to report services to Medicaid and most commercial insurers



Three most common methods of reporting

- 1. Separately on CMS-1500 claim form (device)
- 2. Separately on outpatient UB-04 claim form
- 3. Separate line item on inpatient UB-04 claim form (part of delivery claim


1. Physician use of the CMS-1500 form

21.	DIAGNOSIS	S OR NAT	URE	OF IL	LNESS OR IN	IJURY. Re	late A-	L to service li	ne below (2	24E).			22.	RESUBN CODE	MISSION	ORIG F	REF. NO.	
A.	O13.	4		B.	O09.3	3	C.	O42.0	13	D.	O 6	0.14X0						
E.	Z30.4	430		F.	Z37.0		G.	Z3A.3	5	H.			23.	PRIOR A	UTHORIZ	ATION N	IUMBER	
l.				J.			K.			L.								
24.A. From MM	DATE(S) OF DD	SERVICE YY	To MM	DI	D YY	B. POS		ROCEDURES,SE Explain Unusual (PT		s)	ES	E. DX POINTER	F. \$ C	HARGES	G. DAYS/ UNITS	I. ID QUAL	J. RENDERI PROVIDE	
						21	59	400				ABCDFG			1	NPI		
						24	E O	200	EA						4	NPI		
						21	28	300	51			E						


1. Facility use of the CMS-1500 form

21. [DIAGNOSI	S OR NA	TURE	OF IL	LNESS	OR INJ	URY. Re	late A-	L to service li	ne below (2	24E).			22.	RESUBM CODE	ISSION	ORIG F	REF. NO.	
Α.	Z30.4	430		B.				C.			D.								
E.				F.				G.			H.			23.	PRIOR AI	JTHORIZ <i>I</i>	ATION N	UMBER	
l.				J.				K.			L.								
24.A. From MM	DATE(S) OF	SERVICE YY	To MM	D	D `	ſΥ	B. POS	(E	ROCEDURES,SE Explain Unusual (PT		es)	ES	E. DX POINTER	F. \$ C⊦	ARGES	G. DAYS/ UNITS	I. ID QUAL	J. RENDERI PROVIDE	
							21	J 7	298				Α			1	NPI		
																	LND		
																	NPI		

2. Standard delivery with subdermal implant (UB-04) used for facility-based service charge Bill Type 13x




2. Standard delivery with subdermal implant (UB-04) used for facility-based service charge



2. Standard delivery **with IUD** (UB-04) used for facility-based service charge Bill Type **13X**



2. Standard delivery with IUD (UB-04) used for facility-based service charge





3. A standard delivery with an IUD (UB-04) used for facility-based service charge

42 REV CD	43 DESCRIPTION	44 HCPCS/RATE/HIPPS CODE	45 SERV DATE	46 SERV UNITS	47 TOTAL CHARGES	48 NON-COVERED CHARGES
0110	ROOM AND BOARD	840.00		3	2520 00)
0250	PHARMACY/GENERAL			68	7999 00)
0272	STERILE SUPPLY			3	687 00	
0300	LABORATORY			1	138 00)
0302	LAB/IMMUNOLOGY			4	500 00	
0305	LAB/HEMATOLOGY			2	138 00)
0636	DRUGS/DETAIL CODE	J7297		1	2000.0	
0710	RECOVERY ROOM			5	2247 00)
0720	DELIVERY ROOM/LABOR			1	2372 00	
0721	LABOR			9	2019 00)

^{*}SC fee-for-service Medicaid

OTHER BILLING CONSIDERATIONS

Managed Medicaid & Commercial Payers



Managed Medicaid and Commercial

- Most states have companies that provide coverage to their Medicaid patients
 - States mandate payment policies differently
 - Most publish specific instructions on their website or in the provider manual
 - Internet searches typically produce results easily



Managed Medicaid Instructions



Keystone First

Dear Keystone First Provide

The purpose of this letter is notify you of the hospital reimbursement for long-acting reversible contraception (LARC) and contraceptive implants in addition to the All Patient Refined Diagnosis Related Group (APR-DRG) payment of obstetrical

Effective for dates of service December 1, 2016 and after, services billed during the postpartum timeframe, in an inpatient setting, with the following codes and modifiers will be reimbursed according to the current Department of Human Services (DHS) fee schedule:

Code	Description	Provider Type	Specialty Type	Place of Service	Modifier
J7297	Levonorgestrel-releasing intrauterine contraceptive system, 52 mg, 3 year duration	01	010	22	FP
J7298	Levonorgestrel- releasing intrauterine contraceptive system, 52 mg, 5 year duration	01	010	22	FP
J7300	Intrauterine copper contraceptive	01	010	22	FP
J7301	Levonorgestrel-releasing intrauterine contraceptive system, 13.5 mg	01	010	22	FP
J7307	Etonogestrel (contraceptive) implant system, including implant and supplies	01	010	22	FP
\$4989	Contraceptive intrauterine device (e.g., Progestacert IUD), including implants and supplies	01	010	22	FP

Note: LARC claims are to be submitted in an outpatient hospital claim format using the applicable codes and modifiers

The complete DHS Medical Assistance Bulletin 01-16-33 "MA Program Fee Schedule Updates for Certain Family Planning Services" can be found at: http://www.dhs.pa.gov/publications/bulletinsearch/index.htm

Thank you for your participation in the Keystone First network and your continued commitment to the care of our members. If you have any questions regarding this notification, please contact your Provider Account Executive

Deusi anne

Director, Provider Network Management

Coverage by Vista Health Plan, an independent licensee of the Blue Cross and Blue Shield Association

https://www.keystonefirstpa. com/pdf/provider/communic ations/fastfacts/2017/010417larc-payment.pdf

2000 Market Street, Ste. 850 Philadelphia, PA 19103

aetna

January 16, 2017

AETNA BETTER HEALTH® OF PENNSYLVANIA

Long-acting reversible contraception (LARC) and family planning services reimbursement changes

What has changed?

On November 26, 2016, the Pennsylvania Department of Human Services (DHS) issued a Medical Assistance (MA) Program bulletin notifying providers of positive reimbursement changes for certain family planning and family planning-related services, effective with dates of service on and after

In accordance with these new MA Program fee schedule changes, Aetna Better Health of Pennsylvania

- · Reimburse hospitals separately for the cost of the device when inserting a LARC intrauterine device (IUD) or contraceptive implant at the time of an obstetrical delivery in addition to the All Patient Refined-Diagnosis Related Group (APR-DRG) payment that hospitals receive for the delivery, for dates of service on or after December 1, 2016.
- · Reimburse the professional component fee for insertion of a LARC or contraceptive implant at the time of an obstetrical delivery.
- · Reimburse providers according to MA reimbursement guidelines for certain family planning and family-planning related services rendered for dates of service on or after December 1, 2016.

These changes affect MA enrolled acute care general hospitals and providers who render family planning services to Medical Assistance beneficiaries, which include ABH members. These changes apply retroactively to covered services rendered for dates of service on or after December 1, 2016.

We are updating the ABH claims payment system to comply with DHS reimbursement guidelines to pay providers for covered LARC and certain family planning services in accordance with MA reimbursement practices. We expect these updates to be complete by February 1, 2017.

· Continue to provide family planning options to your members, incorporate LARC counseling, and support access to LARC in all clinically appropriate circumstances.

www.aetnabetterhealth.com/pennsylvania

- Facilities should bill for services on the same inpatient¹ admission claim form. The claim should include the appropriate procedure code(s) as a separate line item(s) on UB-04 form(s). Bill Type 11X
- · Practitioners must bill appropriate procedure code(s) and modifier(s) as a separate line item(s) on CMS-1500 forms.

Place of Service 21

MA Program guidelines: http://dhs.pa.gov/cs/groups/webcontent/documents/document/c_251790.pdf

If you have any questions, call your provider relations representative at 1-866-638-1232, prompt 3, then prompt 5.

Sincerely.

Aetna Better Health of Pennsylvania

Note: Aetna Better Health facility and professional billing requirements differ from MA billing guidelines for LARC services provided in an inpatient setting

www.aetnabetterhealth.com/pennsylvania

https://www.aetnabetterhealth.com /pennsylvania/assets/pdf/provider/n otices/larc-family-planningnotice.pdf



Managed Medicaid and Commercial

- Most states have companies that provide coverage to their Medicaid patients
 - States mandate payment policies differently
 - Most publish specific instructions on their website or in the provider manual
 - Internet searches typically produce results easily
- Commercial insurance companies are:
 - Sometimes working in cooperation with state Medicaid programs
 - Recognizing the financial benefit of avoiding unplanned pregnancies



CONCLUSION

And Resources



Conclusion & Key Takeaways

- ACOG Committee Opinion #670, Immediate Postpartum LARC, states that IPP LARC can reduce unintended pregnancy and lengthen interpregnancy intervals
- We have reached a point where many have identified the benefits of IPP LARC
 - o Objections to it (primarily billing) are being overcome
 - There is no *single* method that all payers use to report this service
- Communicate with your payers to learn their policies
- Where necessary, advocate for them to develop policies for IPP LARC, if policies don't exist



Resources

- CMS issued formal guidance in April 2016
- The objective:
 - Increase the rate and improve the content of postpartum visits
 - Increase access the use of effective methods of contraception

https://www.medicaid.gov/federal-policy-guidance/downloads/cib040816.pdf

DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop S2-26-12 Baltimore, MD 21244-1850



CMCS Informational Bulletin

DATE: April 08, 2016

FROM: Vikki Wachino, Director

Center for Medicaid and CHIP Services

SUBJECT: State Medicaid Payment Approaches to Improve Access to Long-Acting

Reversible Contraception

In July 2014, the Center for Medicaid and CHIP Services (CMCS) launched the Maternal and Infant Health Initiative to improve maternal and infant health outcomes. The initiative has two primary goals: 1) increasing the rate and improving the content of postpartum visits; and 2) increasing access and use of effective methods of contraception. Medicaid provides coverage for more than 70 percent of family planning services for low-income Americans. Given this important role, CMCS sought to identify approaches to Medicaid reimbursement that promote the availability of effective contraception. ¹ This Informational Bulletin describes emerging payment approaches several state Medicaid agencies have used to optimize access and use of long-acting reversible contraception (LARC).

Background

Beyond preventing unplanned pregnancies, research indicates that effective contraception helps prevent poor birth spacing, thereby reducing the risk of low-weight and/or premature birth.² It can also be essential to a woman's long-term physical and emotional well-being. LARCs—intrauterine devices (IUDs) and contraceptive implants—are highly effective methods of birth control that last between 3 and 10 years (depending on the method) without requiring daily, weekly, or monthly user effort.³ The Centers for Disease Control and Prevention has identified LARCs as among the most effective family planning methods with a pregnancy rate of less than 1 pregnancy per 100 women in the first year. For comparison, the contraceptive pill has a rate of 9 pregnancies per 100 women in the first year, while the male condom has rate of 18 pregnancies per 100 women in the first year.⁴ While Medicaid agencies typically reimburse for multiple types of contraception, LARCs possess a number of advantages: they are cost-effective, have

Resources

- **ACOG LARC Program Medicaid** Reimbursement Webpage – click on your state to access instruction from your state's Medicaid program
- **ACOG Postpartum Contraceptive Access Initiative**
- ACOG LARC Program Immediate Postpartum LARC Webpage
- ACOG LARC Program Immediate Postpartum LARC Resource Digest
- ACOG Committee Opinion #670: Immediate Postpartum Long-Acting Reversible Contraception
- ACOG Practice Bulletin #121: Long-Acting Reversible Contraception – Implants and Intrauterine Devices



Women's Health Care Physicians

▶ Contact Us

 Donate ▶ Shop

▶ My ACOG

▶ Career Connection

Search ACOG content

Resources & Publications

Practice Management

Education & Events

Advocacy

For Patients

About ACOG

Medicaid Reimbursement for Postpartum LARC by State

Find an Ob-Gvn Home / About ACOG / ACOG Departments & Activities / Long-Acting Reversible Contraception Program / Medicaid Reimbursement for Postpartum LARC by State

Long-Acting Reversible Contraception Program

About the LARC Program

Advocacy and Policy

Clinical Education and Training

Clinical Resources

Coding and Reimbursement

E-Newsletter

Exhibiting

Immediate Postpartum

Patient Resources

Postpartum Contraceptive Access Initiative

Practice Resources

Webinars


Zika Resources

Medicaid Reimbursement for Postpartum LARC by State

The Department of Health and Human Services' Centers for Medicare & Medicaid Services released this Informational Bulletin on April 8, 2016, detailing payment and policy approaches several state Medicaid agencies have used to optimize access and use of long-acting reversible contraception (LARC) methods.

Medicaid Reimbursement for Postpartum LARC in the Hospital Setting

States in light blue on the map below have published guidance regarding reimbursement for postpartum LARC - click on them for more information.



The ACOG LARC Program can help!

- Email us: pcai@acog.org
- Find more resources online:
 - https://pcainitiative.acog.org
 - https://www.acog.org/programs/long-acting-reversiblecontraception-larc
- Send us your LARC-related questions:
 - owww.acoglarc.freshdesk.com
 - The LARC Program Help Desk is a free service open to all, ACOG members and non-members alike
 - All questions will be responded to within 10 business days.



References

Aiken ARA, Aiken CEM, Trussell J, Guthrie KA. Immediate postpartum provision of highly effective reversible contraception. BJOG 2015;122(8):1050-1.

Bryant AS, Haas JS, McElrath TF, McCormick MC. Predictors of compliance with the postpartum visit among women living in healthy start project areas. Matern Child Health J 2006;10(6):511-6.

Centers for Disease Control and Prevention. Unintended Pregnancy Prevention. 2015. https://www.cdc.gov/reproductivehealth/unintendedpregnancy/

Cohen R, Sheeder J, Arango N, Teal SB, Tocce K. Twelve-month contraceptive continuation and repeat pregnancy among young mothers choosing postdelivery contraceptive implants or postplacental intrauterine devices. Contraception 2016;93(2):178-183.

Connolly A, Thorp J, Pahel L. Effects of pregnancy and childbirth on postpartum sexual function: a longitudinal prospective study. Int Urogynecol J Pelvic Floor Dysfunct. 2005;16:263-7.

Crockett AH, Pickell LB, Heberlein EC, Billings DL, Mills B. Six- and twelve-month documented removal rates among women electing postpartum inpatient compared to delayed or interval contraceptive implant insertions after Medicaid payment reform. Contraception 2017;95(1):71-76.

Dahlke JD, Terpstra ER, Ramseyer AM, Busch JM, Rieg T, Magann EF. Postpartum insertion of levonorgestrel-intrauterine system at three time periods: a prospective randomized pilot study. Contraception. 2011;84(3):244-8.

Finer LB, Zolna MR. Declines in unintended pregnancy in the United States, 2008–2011. New England Journal of Medicine 2016;374(9):843-852.



References

Grimes DA, Lopez LM, Schulz KF, Van Vliet HA, Stanwood NL. Immediate post-partum insertion of intrauterine devices. Cochrane Database Syst Rev 2010;12(5):CD003036.

Guttmacher Institute. September 2016 Fact Sheet: Unintended Pregnancy in the United States. 2016. https://www.guttmacher.org/fact-sheet/unintended-pregnancy-united-states

Immediate postpartum long-acting reversible contraception. Committee Opinion No. 670. American College of Obstetricians and Gynecologists. Obstet Gynecol 2016;128:e32–7.

Kost K. Unintended Pregnancy Rates at the State Level: Estimates for 2010 and Trends Since 2002. Guttmacher Institute 2015.

Long-acting reversible contraception: implants and intrauterine devices. Practice Bulletin No. 121. American College of Obstetricians and Gynecologists. Obstet Gynecol 2011;118:184-96.

Lopez LM, Bernholc A, Hubacher D, Stuart G, Van Vliet HA. Immediate postpartum insertion of intrauterine device for contraception. Cochrane Database of Systematic Reviews. 2015;(6):CD003036.

Los Angeles County Department of Health: Billing and Reimbursement. http://publichealth.lacounty.gov/owh/LARC/ LARCToolkit2019.BillingReimbursement.pdf

McNicholas C, Swor E, Wan L, Peipert JF. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: two years the LARC beyond FDA-approved duration. Am J Obstet Gynecol 2017;216(6):586.e1-586.e6. Paring Reversible Contract

Medicaid Reimbursement for Postpartum LARC by State. ACOG LARC Program. https://www.acog.org/About-ACOG/ ACOG-Departments/Long-Acting-Reversible-Contraception/Immediate-Postpartum-LARC-Medicaid-Reimbursement

References

Medi-Cal. FAQs for DRGs. https://www.dhcs.ca.gov/provgovpart/Documents/DRG/SFY18-19Medi-Cal_DRG_FAQ.pdf

Optimizing postpartum care. Committee Opinion No. 666. American College of Obstetricians and Gynecologists. Obstet Gynecol 2016;127:e187–92.

Tang JH, Dominik R, Re S, Brody S, Stuart GS. Characteristics associated with interest in long-acting reversible contraception in a postpartum population. Contraception 2013;88(1):52-7.

Thiel de Bocanegra H, Chang R, Menz M, Howell M, Darney P. Postpartum contraception in publicly-funded programs and interpregnancy intervals. Obstet Gynecol 2013;122(2 Pt 1):296-303.

Tocce MK, Sheeder JL, Teal SB. Rapid repeat pregnancy in adolescents: do immediate postpartum contraceptive implants make a difference? Am J Obstet Gynecol 2012;206(6):481.e1-7.

White K, Teal SB, Potter JE. Contraception after delivery and short interpregnancy intervals among women in the United States. Obstet Gynecol 2015;125(6):1471–7.

Woo I, Seifert S, Hendricks D, Jamshiki RM, Burke AE, Fox MC. Six-month and 1-year continuation rates following postpartum insertion of implants and intrauterine devices. Contraception 2015;92(6):532-5.

Zerden ML, Tang JH, Stuart GS, Norton DR., Verbiest SB, Brody S. Barriers to receiving long-acting reversible contraception in the postpartum period. Womens Health Issues 2015;25(6):616-21.